Editorial: Helicobacter pylori infection and antibiotic resistance: clinical, translational and experimental studies

Yadegar, Abbas; Nabavi-Rad, Ali; Smith, Sinéad Marian

doi:10.3389/fcimb.2023.1296784

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhibition clear halo zone of HP around the colonies of Lactobacillus acidophilus under microaerophilic conditions for 72 hours was interpreted as the inhibitory effect on Hp and was observed in 13/15 patients (86.67%) [49]. It is known that the other probiotics (mainly Lactobacillus, Saccharomyces boulardii, and Bacillus clausii) have been shown to reduce the side effects of HP eradication therapy, such as diarrhea and abdominal pain, and improve the eradication rates [50][51][52][53][54][55]. However, this opinion was reflected only in the recommendations of the latest international conciliation conference [9].…”

Section: Discussionmentioning

confidence: 99%

Fermented milk product “Narineh” with Lactobacillus acidophilus in sequential and classical therapy for Helicobacter pylori-associated peptic ulcers

Yeganyan,

Avakyan,

Trachtenberg

et al. 2024

BCHD

View full text Add to dashboard Cite

Background: In recent years, there has been a growing dissatisfaction with the classical schemes of the eradication of Helicobacter pylori in ulcerative disease among physicians due to frequent failures in eradication therapy, mostly due to antibiotic resistance. It is a known fact that the Lactobacillus acidophilus inhibits the growth of Helicobacter pylori. Objective: Our main goal was to investigate the ability of the fermented milk product "Narineh,” as a functional food, containing Lactobacillus acidophilus to evaluate the efficiency and incidence of adverse effects in addition to the standard triple scheme of eradication therapy with colloidal bismuth substrate. Methods: The patients with peptic ulcer were divided into 2 groups: control (42 patients) received traditional treatment regimens, including 7 days proton pump inhibitor (PPI) + amoxicillin (A) and clarithromycin (C) in the standard doses and subsequent 14 day De-nol (colloidal bismuth subcitrate); experimental (44 patients) received in addition to this standard conventional scheme "Narineh" - 200g, containing 2x109 Lactobacillus acidophilus one time a day starting from the 8-th day for 4 weeks. The results of the eradication in patients were evaluated after 4 -5 weeks, 6 months, and 12 months after completion of treatment using the C13 respiratory urea test (RUT). Repeated endoscopy with histological biopsies was carried out together with RUT in 4-5 weeks after the completion of treatment, and later (6-12 months) for the identification of recurrent ulcer. Results: The treatment with “Narineh” added to the standard regimen significantly reduces the percentage of reinfection and relapse of the disease with a statistical difference (P<0,05). The combination of fermentation milk product “Narineh”, containing Lactobacillus acidophilus with bismuth subcitrate, doesn’t cause a violation of biocenosis of the large intestine, in contrast to the PPI and antibiotics with a statistical difference (P<0,05). In addition, it provides the normalization of gut biocenosis and reduces the frequency of antibiotic-associated diarrhea and other side effects. Conclusion: The treatment with “Narineh” added to the standard scheme is more effective for eradication of Helicobacter pylori infection and significantly reduces the percentage of reinfection and relapse of the disease and lessens the side effects of medications. Keywords: peptic ulcer, eradication Helicobacter pylori, side effects reinfection, fermented milk product “Narineh”, Lactobacillus acidophilus, functional foods

show abstract

Section: Discussionmentioning

confidence: 99%

Fermented milk product “Narineh” with Lactobacillus acidophilus in sequential and classical therapy for Helicobacter pylori-associated peptic ulcers

Yeganyan,

Avakyan,

Trachtenberg

et al. 2024

BCHD

View full text Add to dashboard Cite

show abstract

“…The infection with H. pylori provokes a chronic inflammatory response and it is the strongest risk factor for the development of gastric cancer [15][16][17]. H. pylori has been classified by the International Agency for Research on Cancer as a class I carcinogen and currently correlated with 80% of malignancies associated to infectious diseases worldwide [18][19][20]. For this reason, eradicative treatment has been indicated, even in cases that patients are asymptomatic, through the application of a test-and-treat strategy tailored to each specific case.…”

Section: Introductionmentioning

confidence: 99%

Bioactive peptides as alternative treatment for Helicobacter pylori infection

Franca-Oliveira,

Hernández-Ledesma,

Martinez-Rodriguez

2024

BCHD

View full text Add to dashboard Cite

The infection and chronic inflammatory response generated by Helicobacter pylori is a global health concern. This pathogen is characterized as a major risk factor in the development of gastric cancer and other diseases. Conventional eradication therapies are based on antibiotic regimens and as a consequence there is an increase in antimicrobial resistance of the pathogen strains, besides other potential side effects for the host. Therefore, it is necessary to explore new alternatives. This review delves into the realm of antimicrobial peptides, exploring their efficacy against H. pylori sourced from diverse origins. Furthermore, it sheds light on food-derived peptides exhibiting remarkable biological activity. These peptides exhibit promising effects on biomarkers associated with H. pylori infection, demonstrating anti-inflammatory and antioxidant properties validated through rigorous testing in both cell and animal models. Regarding the anti-inflammatory activity, the peptide VPY derived from soybean and the peptides derived from animal sources such as meat (β-Ala-His), egg (DEDTQAMPFR, DEDTQAMPF, MLGATSL, MSYSAGF, CR, FL, HC, LL, MK) and milk (IPAV) have reported a reduction of the cytokine IL-8, biomarker directly related to H. infection. For the antioxidant activity, peptides derived from milk (EAMAPK, AVPYPQ) and from Spirulina maxima (LDAVNR, MMLDF) have reduced ROS levels and could have a positive effect on the control of H. infection. Food-derived bioactive peptides with an anti-adhesive effect were also discussed. They derive from vegetable sources (corn, pea and wheat) and are capable of interacting with the host cells, interfering the adherence of H. pylori. Food-derived bioactive peptides have potential to avoid and/or mitigate undesired outcomes of infectious diseases due to the possibility of its application in nutraceuticals and food products, resulting in a preventive approach. Keywords: Helicobacter pylori, antibiotic resistance, bioactive peptides, antimicrobial peptides

show abstract

Editorial: Helicobacter pylori infection and antibiotic resistance: clinical, translational and experimental studies

Cited by 2 publications

References 7 publications

Fermented milk product “Narineh” with Lactobacillus acidophilus in sequential and classical therapy for Helicobacter pylori-associated peptic ulcers

Fermented milk product “Narineh” with Lactobacillus acidophilus in sequential and classical therapy for Helicobacter pylori-associated peptic ulcers

Bioactive peptides as alternative treatment for Helicobacter pylori infection

Contact Info

Product

Resources

About